Novartis AG ADR (NVS)vsBio-Techne Corp (TECH)
NVS
Novartis AG ADR
$148.38
-0.96%
HEALTHCARE · Cap: $273.77B
TECH
Bio-Techne Corp
$51.99
-2.24%
HEALTHCARE · Cap: $8.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 4573% more annual revenue ($56.58B vs $1.21B). NVS leads profitability with a 23.9% profit margin vs 9.1%. TECH appears more attractively valued with a PEG of 0.74. TECH earns a higher WallStSmart Score of 58/100 (C).
NVS
Hold49
out of 100
Grade: D+
TECH
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Margin of Safety
+68.6%
Fair Value
$201.82
Current Price
$51.99
$149.83 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Earnings expanding 128.6% YoY
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Growing faster than its price suggests
Strong operational efficiency at 25.2%
Areas to Watch
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
ROE of 5.3% — below average capital efficiency
Weak financial health signals
Premium valuation, high expectations priced in
Revenue declined 1.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : TECH
The strongest argument for TECH centers on EPS Growth, Altman Z-Score, Debt/Equity. PEG of 0.74 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Bear Case : TECH
The primary concerns for TECH are Return on Equity, Piotroski F-Score, P/E Ratio. A P/E of 77.1x leaves little room for execution misses.
Key Dynamics to Monitor
NVS profiles as a declining stock while TECH is a value play — different risk/reward profiles.
TECH carries more volatility with a beta of 1.36 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
TECH scores higher overall (58/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Bio-Techne Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments, and services for the global clinical diagnostic and research markets. The company is headquartered in Minneapolis, Minnesota.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?